# Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

> **NCT06398925** · PHASE1 · COMPLETED · sponsor: **Oxford Cannabinoid Technologies Holdings PLC** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** OCT461201 50 mg
- **DRUG:** OCT461201 100 mg
- **DRUG:** OCT461201 150 mg
- **DRUG:** OCT461201 450 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06398925
- **Lead sponsor:** Oxford Cannabinoid Technologies Holdings PLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-26
- **Primary completion:** 2023-09-25
- **Final completion:** 2023-09-25
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06398925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06398925, "Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06398925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*